Startup Omada Health to start prescribing GLP-1s, other obesity medications as membership grows

Core Insights - Omada Health will begin prescribing GLP-1s and other obesity medications, expanding its weight management program as membership surpasses 100,000 [1][6] Industry Overview - The digital health sector is increasingly entering the GLP-1 market, which could reach approximately $100 billion by the end of the decade [2] - Major manufacturers like Eli Lilly and Novo Nordisk are working to enhance accessibility and develop new treatments for obesity and chronic conditions [2] Company Strategy - Omada's CEO, Sean Duffy, believes that access to GLP-1s will significantly increase over time, with a market expansion expected to include pills and next-generation treatments [3] - The company aims to support lifestyle and behavioral changes for patients on GLP-1s, providing resources such as nutrition guidance and health coaching [4] Patient Support - The new offering will assist patients from the prescription stage through their treatment, addressing complexities and side effects associated with GLP-1 injections [5] - Omada collaborates with licensed providers trained in obesity care to enhance medication management for patients [4][5] Financial and Operational Context - Omada partners with health plans and employers to better support employee health needs while managing costs related to obesity treatments [6] - The company reported its quarterly earnings for the second time since its IPO in June [6][7]